The Opthea (ASX:OPT) share price up after receiving FDA approval

The Opthea Ltd (ASX: OPT) share price opened higher on Wednesday after receiving an important regulatory waiver from the US FDA
The post The Opthea (ASX:OPT) share price up after receiving FDA approval appeared first on The Motley Fool Australia. –

Five stacked building blocks with green arrows, indicating rising inflation or share prices

The Opthea Ltd (ASX: OPT) share price is up 8.39% to $1.55 this morning. The rise comes after receiving an initial Pediatric Study Plan (iPSP) waiver from the US Food and Drug Administration (FDA) for OPT-302. 

Opthea is committed to improving vision in patients suffering from retinal eye diseases. OPT-302 is the company’s lead product candidate. The product also has the potential to address the unmet medical need within the eye disease market. 

Another milestone for the Opthea share price 

An iPSP is a pre-requisite for a marketing application of new medicine for a biopharmaceutical company in the US. Additionally, the iPSP provides the FDA with details regarding the company’s proposed strategy. In particular, for the investigation of a new medical product in a pediatric population. 

On Wednesday, Opthea received an iPSP waiver for OPT-302. This applied to all subsets of the pediatric population (full pediatric age group from birth to <17 years) for the treatment of wet age-related macular degeneration (wet AMD), a leading cause of visual impairment in the developed world in people over the age of 50. 

Wet AMD affects approximately 1 million people in the United States and 2.5 million in Europe. Furthermore, the company believes that the global aging population will result in a significant increase in the number of wet AMD cases. The disease affects central vision and the ability to see fine detail. Wet AMD is caused by abnormal growth and leakage of blood vessels. This occurs at the back of the eye, which results in degeneration of the retina and vision loss. 

Comments from the CEO

The iPSP waver means Opthea will not have to conduct an additional study in the pediatric population. Opthea CEO, Dr. Megan Baldwin commented on the waiver: 

The agreed iPSP waiver is an important regulatory milestone in the US that is required to be completed before Opthea is able to submit a marketing application for OPT-302 to the FDA. Opthea will continue the process to further fulfilling regulatory requirements by focusing on our pivotal Phase 3 clinical trials in adult patients that are designed to support potential marketing approval of OPT-302 for the treatment of wet AMD.


Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post The Opthea (ASX:OPT) share price up after receiving FDA approval appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!